CGON Competitors

Stocks USA . 
Stock . CG Oncology Common
CGON Stock   51.50  0.12  0.23%   
CG Oncology Common competes with Centessa Pharmaceuticals, Travere Therapeutics, Legend Biotech, and Disc Medicine; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing CG Oncology competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of CG Oncology to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.

CG Oncology vs Tarsus Pharmaceuticals Correlation

Pay attention - limited upside

The correlation between CG Oncology Common and TARS is -0.78 (i.e., Pay attention - limited upside) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding CG Oncology Common and TARS in the same portfolio, assuming nothing else is changed.

Moving together with CGON Stock

  0.73GXEA Galapagos NVPairCorr
  0.88VP1 AVRICORE HEALTH INCPairCorr

Moving against CGON Stock

  0.53CDIOW Cardio DiagnosticsPairCorr
  0.45VCYT VeracytePairCorr
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
47.0051.7356.46
Details
Intrinsic
Valuation
LowRealHigh
46.3563.1067.83
Details

CG Oncology Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between CG Oncology and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of CGON and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of CG Oncology Common does not affect the price movement of the other competitor.

High positive correlations

LEGN
+ 0.94
AAPG
IRON
+ 0.83
RARE
IRON
+ 0.8
CNTA
IRON
+ 0.79
AAPG
RARE
+ 0.79
CNTA
RARE
+ 0.75
AAPG
  

High negative correlations

LEGN
- 0.67
CELC
AAPG
- 0.62
CELC
TARS
- 0.55
CELC
TVTX
- 0.54
CELC
RARE
- 0.52
CELC
IRON
- 0.47
CELC

Risk-Adjusted Indicators

There is a big difference between CGON Stock performing well and CG Oncology Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze CG Oncology's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
CELC  2.07  0.20  0.07  0.49  2.20 
(2.48)
 3.95 
(3.08)
 17.89 
AAPG  2.65 (0.48) 0.00 (2.08) 0.00 
 0.00 
 5.25 
(6.36)
 16.72 
CNTA  1.87 (0.14) 0.00  1.57  0.00 
 0.00 
 3.39 
(3.05)
 13.05 
APGE  2.06  0.07  0.01  0.16  3.17 
(2.15)
 4.97 
(4.24)
 20.16 
XENE  1.64  0.02 (0.01) 0.12  1.93 
(1.72)
 3.29 
(2.67)
 10.56 
TVTX  2.66 (0.33) 0.00 (0.21) 0.00 
 0.00 
 5.65 
(6.98)
 28.55 
RARE  3.25 (0.58) 0.00 (0.31) 0.00 
 0.00 
 7.73 
(4.30)
 51.23 
LEGN  2.58 (0.81) 0.00 (13.46) 0.00 
 0.00 
 3.97 
(6.84)
 19.65 
IRON  2.54 (0.73) 0.00 (1.10) 0.00 
 0.00 
 4.33 
(7.75)
 14.87 
TARS  1.59 (0.35) 0.00 (0.44) 0.00 
 0.00 
 3.48 
(3.91)
 10.88 

CG Oncology Competitive Analysis

The better you understand CG Oncology competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, CG Oncology's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across CG Oncology's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
CGON CELC AAPG CNTA APGE XENE TVTX RARE LEGN IRON
 0.23 
 51.50 
CGON
 0.34 
 104.51 
Celcuity
 2.67 
 23.82 
Ascentage
 1.90 
 24.71 
Centessa
 2.21 
 67.78 
Apogee
 0.34 
 41.48 
Xenon
 9.08 
 27.82 
Travere
 12.68 
 20.52 
Ultragenyx
 2.66 
 17.58 
Legend
 21.91 
 55.95 
Disc
Market Volatility
(90 Days Market Risk)
Very steady
Very steady
Not too volatile
Very steady
Very steady
Very steady
Not too volatile
Not too volatile
Not too volatile
Very steady
Market Performance
(90 Days Performance)
Fair
Mild
Weakest
Weakest
Soft
Weak
Weakest
Weakest
Weakest
Weakest
Odds of Financial Distress
(Probability Of Bankruptcy)
Small
Low
Risky
Low
Small
Small
High
Low
Small
Small
Current Valuation
(Equity Enterprise Value)
Under Valued
Under Valued
Under Valued
Under Valued
Under Valued
Under Valued
Under Valued
Under Valued
Under Valued
Under Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Strong Buy
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Strong Hold
Strong Buy
Strong Sell
Cautious Hold
Hold
Strong Hold
Cautious Hold
Hold
Strong Sell
Cautious Hold
Current Ratio
N/A
17.34
N/A
15.48
N/A
57.86
4.71
3.08
3.83
N/A
Net Asset
754.8 M
245.12 M
2.62 B
576.8 M
753.95 M
798.14 M
594.12 M
1.5 B
1.67 B
496.77 M
Profit Margin
N/A
N/A
-2.97
N/A
N/A
N/A
-0.2
-0.92
-0.26
N/A
EBITDA
(114.63 M)
(101.37 M)
(237.63 M)
(221.88 M)
(216.68 M)
(235.86 M)
(265.77 M)
(535 M)
(113.16 M)
(108.27 M)
Operating Margin
-30.69
N/A
-2.37
-14.25
N/A
-45.44
0.15
-1.07
-0.16
N/A
Current Valuation
3.59 B
4.72 B
2.21 B
3.46 B
4.22 B
2.76 B
2.81 B
1.88 B
2.75 B
2.12 B
Price To Book
6.43
41.49
22.38
11.9
7.68
5.74
37.22
247.7
3.39
4.72
Retained Earnings
(217.98 M)
(271.86 M)
(5.77 B)
(988.7 M)
(305.92 M)
(899.47 M)
(1.45 B)
(3.96 B)
(1.66 B)
(298 M)
Current Asset
N/A
11.89 M
N/A
N/A
N/A
60.87 M
N/A
416.79 M
N/A
N/A
Beta
1.34
0.38
0.88
1.57
1.43
0.93
0.81
0.16
0.091
2.58
Number Of Employees
113
87
605
114
196
316
385
1.29 K
2.9 K
142
Shares Outstanding
82.62 M
46.27 M
92.96 M
146.08 M
54.83 M
77.28 M
89.47 M
96.48 M
184.69 M
37.75 M
Cash Flow From Operations
(78.71 M)
(83.47 M)
(111.36 M)
(142.06 M)
(171.17 M)
(181.39 M)
(237.47 M)
(414.19 M)
(144.03 M)
(93.93 M)
Total Debt
238 K
97.95 M
1.67 B
117.23 M
11.83 M
9.02 M
401.58 M
40.34 M
350.6 M
30 M
Return On Equity
-0.25
-1.22
-1.6
-0.61
-0.38
-0.45
-4.11
-3.13
-0.23
-0.35
Return On Asset
-0.18
-0.27
-0.23
-0.25
-0.25
-0.3
-0.11
-0.25
-0.0692
-0.23
Number Of Shares Shorted
9.24 M
9.84 M
725
6.19 M
8.91 M
5.54 M
14.49 M
9.1 M
21.42 M
4.1 M
Book Value Per Share
8.79
2.7
0.28
2.24
9.89
7.26
0.82
0.095
5.48
16.38
Current Liabilities
N/A
456.69 K
N/A
N/A
N/A
2.78 M
N/A
50.43 M
N/A
N/A
Total Asset
754.8 M
245.12 M
2.62 B
576.8 M
753.95 M
798.14 M
594.12 M
1.5 B
1.67 B
496.77 M
Short Ratio
6.37
12.91
0.2
3.88
8.11
5.32
4.89
2.77
7.25
7.82
Target Price
79.86
114.2
45.71
39.62
104.29
55.82
42.36
64.0
60.6
122.08
Debt To Equity
N/A
0.28
N/A
0.16
N/A
0.01
2.6
0.055
0.29
N/A
Shares Owned By Institutions
97.1
87.72
0.07
88.79
93.9
99.9
99.24
96.87
48.71
92.21
Market Capitalization
4.27 B
4.85 B
2.17 B
3.54 B
4.74 B
3.22 B
2.74 B
2.27 B
3.34 B
2.7 B
Price To Earning
N/A
-23.45
N/A
N/A
N/A
-1.75
N/A
-6.9
N/A
N/A
Price To Earnings To Growth
N/A
-0.18
N/A
N/A
N/A
-0.06
-0.02
-0.24
N/A
N/A
Price To Sales
1961.85
N/A
5.56
236.16
N/A
428.82
6.28
3.6
3.67
N/A
Net Income
(88.04 M)
(111.78 M)
(395.25 M)
(235.76 M)
(182.15 M)
(234.33 M)
(320.63 M)
(569.18 M)
(158.13 M)
(109.36 M)
Earnings Per Share
-2.05
-3.68
-2.1
-1.89
-4.38
-3.89
-1.03
-5.93
-1.28
-5.37
Shares Owned By Insiders
2.9
10.99
N/A
0.52
6.1
0.1
0.76
3.13
1.3
7.79
Revenue
1.14 M
N/A
980.65 M
N/A
N/A
N/A
233.18 M
673 M
627.24 M
N/A
Working Capital
732.84 M
212.85 M
307.55 M
478.41 M
501.15 M
599.67 M
215.95 M
472.97 M
1.01 B
470.3 M
Cash And Equivalents
N/A
66.93 M
N/A
484.16 M
N/A
788.24 M
553.17 M
542.8 M
791.26 M
N/A
Cash Per Share
N/A
4.48
N/A
5.13
N/A
12.66
8.65
7.75
5.11
N/A
Gross Profit
(112.89 M)
N/A
354.93 M
15 M
N/A
(265.21 M)
215.28 M
(163.82 M)
132.68 M
N/A
Day Typical Price
51.62
105.14
24.08
24.86
68.58
41.91
28.84
21.1
17.86
56.64
Accumulation Distribution
0.0415
0.0426
0.0393
0.0671
0.0617
0.0359
406194.0
0.15
0.0477
0.46
Market Facilitation Index
2.19
4.59
0.97
1.73
4.39
1.54
0.0
3.56
0.88
33.97
Daily Balance Of Power
(0.05)
(0.08)
0.6392
0.2659
(0.35)
(0.09)
(0.67)
(0.84)
(0.55)
(0.46)
Period Momentum Indicator
(0.12)
(0.36)
0.62
0.46
(1.53)
(0.14)
(2.78)
(2.98)
(0.48)
(15.70)
Rate Of Daily Change
1.0
1.0
1.03
1.02
0.98
1.0
0.91
0.87
0.97
0.78
Day Median Price
51.68
105.46
24.21
24.94
68.99
42.13
29.36
21.39
18.0
56.99
Price Action Indicator
(0.23)
(1.12)
(0.07)
0.005
(1.97)
(0.72)
(2.93)
(2.36)
(0.66)
(8.88)
Coefficient Of Variation
1019.88
1137.69
(765.42)
(1,844)
2552.72
3700.85
(1,606)
(1,418)
(431.95)
(605.37)
Mean Deviation
2.89
2.07
2.65
1.87
2.06
1.64
2.66
3.25
2.58
2.54
Jensen Alpha
0.386
0.204
(0.48)
(0.14)
0.068
0.0231
(0.33)
(0.58)
(0.81)
(0.73)
Total Risk Alpha
0.1024
0.0275
(0.73)
(0.33)
(0.12)
(0.11)
(0.54)
(0.98)
(1.06)
(0.99)
Sortino Ratio
0.1403
0.0728
N/A
N/A
0.0149
(0.01)
N/A
N/A
N/A
N/A
Downside Variance
7.87
5.6
N/A
N/A
11.34
4.21
N/A
N/A
N/A
N/A
Standard Deviation
4.73
2.75
3.5
2.47
3.06
2.06
3.92
6.71
3.45
4.11
Kurtosis
22.56
2.22
0.7576
1.37
4.13
0.2763
4.23
25.71
1.13
11.57
Potential Upside
4.98
3.95
5.25
3.39
4.97
3.29
5.65
7.73
3.97
4.33
Treynor Ratio
0.403
0.4939
(2.08)
1.57
0.1568
0.1215
(0.21)
(0.31)
(13.46)
(1.10)
Maximum Drawdown
34.61
17.89
16.72
13.05
20.16
10.56
28.55
51.23
19.65
14.87
Variance
22.34
7.59
12.27
6.12
9.39
4.23
15.34
45.04
11.87
16.91
Market Risk Adjusted Performance
0.413
0.5039
(2.07)
1.58
0.1668
0.1315
(0.20)
(0.30)
(13.45)
(1.09)
Risk Adjusted Performance
0.0874
0.078
(0.1)
(0.04)
0.039
0.0279
(0.04)
(0.05)
(0.18)
(0.13)
Skewness
3.81
0.4166
(0.11)
(0.37)
(0.88)
(0.02)
(0.20)
(3.90)
(0.29)
(2.62)
Semi Deviation
2.47
2.2
N/A
N/A
3.17
1.93
N/A
N/A
N/A
N/A
Information Ratio
0.0833
0.0625
(0.15)
(0.08)
0.0163
(0.01)
(0.08)
(0.08)
(0.25)
(0.18)
Value At Risk
(4.40)
(3.08)
(6.36)
(3.05)
(4.24)
(2.67)
(6.98)
(4.30)
(6.84)
(7.75)
Expected Short fall
(3.69)
(2.48)
N/A
N/A
(2.15)
(1.72)
N/A
N/A
N/A
N/A
Downside Deviation
2.81
2.37
N/A
N/A
3.37
2.05
N/A
N/A
N/A
N/A
Semi Variance
6.08
4.86
N/A
N/A
10.08
3.74
N/A
N/A
N/A
N/A

CG Oncology Competition Performance Charts

Five steps to successful analysis of CG Oncology Competition

CG Oncology's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by CG Oncology Common in relation to its competition. CG Oncology's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of CG Oncology in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact CG Oncology's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to CG Oncology Common, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your CG Oncology position

In addition to having CG Oncology in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Cryptocurrency ETFs Thematic Idea Now

Cryptocurrency ETFs
Cryptocurrency ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Cryptocurrency ETFs theme has 123 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Cryptocurrency ETFs Theme or any other thematic opportunities.
View All  Next Launch
When determining whether CG Oncology Common offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of CG Oncology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cg Oncology Common Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cg Oncology Common Stock:
How To Invest In CGON
Details
Is CGON Stock a good investment?
Details
What is CG Oncology's Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out CG Oncology Correlation with its peers.
You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Will Biotechnology sector continue expanding? Could CGON diversify its offerings? Factors like these will boost the valuation of CG Oncology. Projected growth potential of CGON fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every CG Oncology data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Investors evaluate CG Oncology Common using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating CG Oncology's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause CG Oncology's market price to deviate significantly from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Technical
Analysis
Details
It's important to distinguish between CG Oncology's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding CG Oncology should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, CG Oncology's market price signifies the transaction level at which participants voluntarily complete trades.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY